Genmab reported DKK306M in Net Income for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Agios Pharmaceuticals AGIO:US $ -86.22M 1960.54M
Alexion Pharmaceuticals ALXN:US $ 636M 100.2M
Amarin AMRN:US $ 7.81M 9.43M
Amgen AMGN:US $ 464M 1182M
AstraZeneca AZN:LN 550M 1011M
Bayer BAYN:GR € -2335M 4424M
Biomarin Pharmaceutical BMRN:US $ 12.94M 4.43M
Bluebird Bio BLUE:US $ -241.7M 35.89M
Exelixis EXEL:US $ 96.09M 94.49M
Fresenius Medical Care FME:GR € 219M 30M
Galapagos GLPG:NA € -64.33M 73.69M
Genmab GEN:DC DK 306M 790M
GlaxoSmithKline GSK:LN 1395M 322M
GN Store Nord GN:DC DK 427M 47M
GRIFOLS GRF:SM € 136.88M 6.94M
H. Lundbeck A/S LUN:DC 378M 243M
Hikma Pharmaceutical HIK:LN 248M 29M
Immunogen IMGN:US $ -30.74M 3.31M
Insmed INSM:US $ -117321000 25.68M
Lonza Group LONN:SW 319M 73M
Merck MRK:GR € 745M 2M
Novartis NOVN:VX SF 2896M 837M
Regeneron Pharmaceuticals REGN:US $ 3098.9M 1983.7M
Seattle Genetics SGEN:US $ -84.58M 36.84M
William Demant Holding WDH:DC 1.17B 172M